Biogen Idec India bags DCGI approval for Avonex pen

Read Article

Our News BureauMumbai

Biogen Idec Biotech India (Biogen Idec India) announced the approval of the first single-use, intramuscular autoinjector for interferon beta-1a, from Drug Controller General of India (DCGI) to be used by patients with multiple sclerosis (MS) in India. The new device, known as Avonex pen , represents a significant new administration option for MS patients in India.
The new autoinjector is designed to enable easier, more convenient interferon beta-1a administration, improving the treatment experience for MS patients. It was approved based on data from a specific clinical study supporting its effectiveness as a new treatment administration option. Biogen Idec recently received approval in the US and European Union, for the autoinjector. It is hoped that the autoinjector will help ease administration for patients who use interferon beta-1a therapy and those who otherwise may skip treatment due to fear of needle.
“Interferon beta-1a has been an effective treatment with an established safety profile for MS patients for more than five years in India. The approval of this first single-use, intramuscular autoinjector is an important milestone in Biogen Idec’s ongoing drive to bring new innovations to MS patients. Launching Avonex pen, is part of our company’s long-standing commitment to improve the lives of MS patients in India,” said Sameer Savkur, Managing Director, Biogen Idec India.

Comments (0)
Add Comment